Tags

Type your tag names separated by a space and hit enter

Lack of efficacy of the standard potency Edmonston-Zagreb live, attenuated measles vaccine in African infants.
Bull World Health Organ. 1991; 69(2):221-7.BW

Abstract

The efficacy of standard potency Edmonston-Zagreb (E-Z) measles vaccine was tested in a randomized trial of Black infants in a rural area of South Africa where a measles epidemic was occurring. The following immunization schedules were used: 48 infants aged 4-8.5 months who received 3.9 log 50 infectious units of E-Z vaccine (group A); 48 infants aged 4-8.5 months who received 3.28 log 50 infectious units of Schwarz vaccine (group B); and 28 infants aged greater than 9 months who received 3.28 log 50 infectious units of Schwarz vaccine and served as controls (group C). For infants aged less than 23 weeks who were given either the E-Z or Schwarz vaccine, the number of seropositives was low (28%), irrespective of the pre-vaccination level of measles antibody. There was a higher number of seropositives (68%) among those in the age range greater than 23 weeks to less than 36 weeks who received the E-Z vaccine rather than the Schwarz vaccine (36%). When administered to children aged greater than 36 weeks, the Schwarz vaccine produced a satisfactory, though suboptimal response rate (61%). There was no correlation between seropositivity and pre-vaccination measles antibody status. Use of the standard dose of E-Z vaccine may have been one of the factors for this poor response, and this supports the WHO recommendation that titres higher than the standard potency vaccine are needed if 6-month-old infants are to be successfully immunized against measles.

Authors+Show Affiliations

Department of Paediatrics and Child Health, Faculty of Medicine, University of Natal, Durban, South Africa.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

1860150

Citation

Kiepiela, P, et al. "Lack of Efficacy of the Standard Potency Edmonston-Zagreb Live, Attenuated Measles Vaccine in African Infants." Bulletin of the World Health Organization, vol. 69, no. 2, 1991, pp. 221-7.
Kiepiela P, Coovadia HM, Loening WE, et al. Lack of efficacy of the standard potency Edmonston-Zagreb live, attenuated measles vaccine in African infants. Bull World Health Organ. 1991;69(2):221-7.
Kiepiela, P., Coovadia, H. M., Loening, W. E., Coward, P., Botha, G., Hugo, J., & Becker, P. J. (1991). Lack of efficacy of the standard potency Edmonston-Zagreb live, attenuated measles vaccine in African infants. Bulletin of the World Health Organization, 69(2), 221-7.
Kiepiela P, et al. Lack of Efficacy of the Standard Potency Edmonston-Zagreb Live, Attenuated Measles Vaccine in African Infants. Bull World Health Organ. 1991;69(2):221-7. PubMed PMID: 1860150.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lack of efficacy of the standard potency Edmonston-Zagreb live, attenuated measles vaccine in African infants. AU - Kiepiela,P, AU - Coovadia,H M, AU - Loening,W E, AU - Coward,P, AU - Botha,G, AU - Hugo,J, AU - Becker,P J, PY - 1991/1/1/pubmed PY - 1991/1/1/medline PY - 1991/1/1/entrez SP - 221 EP - 7 JF - Bulletin of the World Health Organization JO - Bull World Health Organ VL - 69 IS - 2 N2 - The efficacy of standard potency Edmonston-Zagreb (E-Z) measles vaccine was tested in a randomized trial of Black infants in a rural area of South Africa where a measles epidemic was occurring. The following immunization schedules were used: 48 infants aged 4-8.5 months who received 3.9 log 50 infectious units of E-Z vaccine (group A); 48 infants aged 4-8.5 months who received 3.28 log 50 infectious units of Schwarz vaccine (group B); and 28 infants aged greater than 9 months who received 3.28 log 50 infectious units of Schwarz vaccine and served as controls (group C). For infants aged less than 23 weeks who were given either the E-Z or Schwarz vaccine, the number of seropositives was low (28%), irrespective of the pre-vaccination level of measles antibody. There was a higher number of seropositives (68%) among those in the age range greater than 23 weeks to less than 36 weeks who received the E-Z vaccine rather than the Schwarz vaccine (36%). When administered to children aged greater than 36 weeks, the Schwarz vaccine produced a satisfactory, though suboptimal response rate (61%). There was no correlation between seropositivity and pre-vaccination measles antibody status. Use of the standard dose of E-Z vaccine may have been one of the factors for this poor response, and this supports the WHO recommendation that titres higher than the standard potency vaccine are needed if 6-month-old infants are to be successfully immunized against measles. SN - 0042-9686 UR - https://www.unboundmedicine.com/medline/citation/1860150/Lack_of_efficacy_of_the_standard_potency_Edmonston_Zagreb_live_attenuated_measles_vaccine_in_African_infants_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/1860150/ DB - PRIME DP - Unbound Medicine ER -